Merus N.V.
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:
Guggenheim Healthcare Talks 2021 Oncology Days (Fireside chat): Friday, Feb. 12 at 10:30-10:55 a.m. ET
LifeSci Partners Precision Oncology Day (Presentation): Wednesday, Feb. 17 at 10:30-10:55 a.m. ET
2021 SVB Leerink Global Healthcare Conference (Presentation): Friday, Feb. 26 at 8:40-9:10 a.m. ET
The live webcasts of the presentations will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and
https://twitter.com/MerusNV.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Kvika banki hf.26.2.2021 20:01:34 CET | Press release
Kvika banki hf: Two provisos in Kvika, TM and Lykill Merger Agreement fulfilled
Junshi Biosciences26.2.2021 18:37:02 CET | Press release
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
F. Hoffmann-La Roche Ltd26.2.2021 18:31:32 CET | Press release
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Pro Kapital Grupp26.2.2021 18:01:31 CET | Press release
Pro Kapital Council approved Consolidated Interim Report for IV Quarter and 12 Months of 2020 (Unaudited)
Cargotec Corporation26.2.2021 17:41:40 CET | Press release
Cargotec Corporation: Share Repurchase 26.2.2021
Leasinvest Real Estate Comm. VA26.2.2021 17:41:29 CET | Press release
Leasinvest Real Estate SCA sells the semi-industrial part of the Brixton Business Park in Zaventem
International Petroleum Corporation26.2.2021 17:31:29 CET | Press release
International Petroleum Corporation Announces Updated Share Capital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom